NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
(Total Views: 261)
Posted On: 11/08/2019 5:07:29 PM
NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Leverages Extensive Database, Artificial Intelligence to Identify Applicable Cancer Treatments
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting the most effective drug treatments for cancer patients. An article discussing the company reads, “One disruptive aspect of POAI’s technology is that it helps the clinician to increase the chance of choosing more effective therapy, resulting in potential reduction of side-effects as well as cost savings. Traditionally oncologists prescribe what drugs they think have the best chance at beating a patient’s cancer, and the drug may or may not prove effective. Meanwhile, the patient’s undergoes chemotherapy with often debilitating side effects. If the drug proves to be a poor fit for the patient’s cancer, the chemotherapy experience will have been in vain, and the patient must continue acting as a guinea pig in experimenting with the next likely drug candidate. This is the standard cancer treatment of today. However, by utilizing POAI’s innovative tumor-profiling platform, which literally performs chemotherapy on the patient’s tumor outside the body to determine which drug is most effective, the patient can be spared many of the risks of being a ‘guinea-pig’ as the oncologist attempts different drugs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, is utilizing the combined capabilities of AI with its extensive database of tumor data to assist clinicians in selecting the most effective drug treatments for cancer patients. An article discussing the company reads, “One disruptive aspect of POAI’s technology is that it helps the clinician to increase the chance of choosing more effective therapy, resulting in potential reduction of side-effects as well as cost savings. Traditionally oncologists prescribe what drugs they think have the best chance at beating a patient’s cancer, and the drug may or may not prove effective. Meanwhile, the patient’s undergoes chemotherapy with often debilitating side effects. If the drug proves to be a poor fit for the patient’s cancer, the chemotherapy experience will have been in vain, and the patient must continue acting as a guinea pig in experimenting with the next likely drug candidate. This is the standard cancer treatment of today. However, by utilizing POAI’s innovative tumor-profiling platform, which literally performs chemotherapy on the patient’s tumor outside the body to determine which drug is most effective, the patient can be spared many of the risks of being a ‘guinea-pig’ as the oncologist attempts different drugs.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)